Utility of individualized homoeopathic medicine in the management of Essential Hypertension including miasmatic analysis based on J H Allen
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
Essential hypertension is a major public health problem and a leading risk factor for cardiovascular morbidity and mortality. This study aims to evaluate the utility of individualized homoeopathic medicines in the management of essential hypertension using miasmatic analysis based on J H Allen. It is a prospective single arm open label interventional study to be conducted. Thirty patients aged 25 to 60 years diagnosed with essential hypertension pre hypertension and Stage I will be enrolled as per inclusion and exclusion criteria. Individualized homoeopathic medicines will be prescribed in centesimal potency based on detailed case taking and miasmatic evaluation. Patients will be followed up every 15 days for a period of 18 months. The primary outcome measure will be change in systolic and diastolic blood pressure and the secondary outcome will be assessment of quality of life using the WHOQOL BREF questionnaire. The study intends to assess the effectiveness and potential role of individualized homoeopathic treatment in improving blood pressure control and overall quality of life in patients with essential hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 盲法
- None
入排标准
- 年龄范围
- 25.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •1 Patients suffering from essential hypertension pre hypertensives SBP 120 to 139 mm Hg and DBP 80 to 89 mm Hg and stage I hypertensives SBP 140 to 159 mm Hg and DBP 90 to 99 mm Hg 2 Whose history examination and routine investigations revealed no evidence of obvious secondary causes 3 Patients who are willing for inclusion in the study and giving consent to participate and willing for regular follow ups.
排除标准
- •1 Pregnant or lactating women with essential hypertension 2 Patients with severe essential hypertension 3 Patients with secondary hypertension 4 Patients who require emergency medical interventions or Severe Co morbidities.
- •Simultaneous participation in other clinical studies or completion of Participation in a study less than 6 months prior 5 Patients with autoimmune disorder.
研究者
Dr Varun Tyagi
State National Homoeopathic Medical College and Hospital Lucknow